USPTO serial 79342715
PHINDER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 12, 2024
- Examiner
- HARMON, RAYMOND E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PHINDER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joseph G. Chu
Joseph G. Chu JCIP155 N Lake Avenue, Suite 800Pasadena, CA 91101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical and veterinary use or purposes; reactants for medical and veterinary diagnosis, namely, reagents for medical use; diagnostic preparations for medical use for sale in kit form; diagnostic products for medical purposes, namely, medical diagnostic reagents; indicators for medical diagnosis, namely, medical diagnostic reagents; veterinary diagnostic reagents; reagents in kit form for conducting Real Time Polymerase Chain Reaction assays (RT-PCR) for medical or veterinary purposes; reagents for medical or veterinary purposes; reagents for use in diagnostic tests for medical or veterinary purposes; medical diagnostic reagents for testing of body fluids; stem cells for medical and veterinary purposes; substances for use in genetic probe assay kits for medical use, namely, reagents for use in medical testing; preparations for medical diagnostic use; biochemical diagnostic preparations for medical diagnostic use; products for medical diagnosis, namely, medical diagnostic reagents; diagnostic agents for pharmaceutical use; test reagents for medical diagnosis; diagnostic biomarker reagents for medical purposes; chemical preparations for diagnostic purposes; chemical preparations for use in RNA and DNA analysis, namely, reagents for use in medical testing; chemical products for medical analysis, namely, reagents for use in medical testing; preparations for detecting genetic predispositions for medical purposes; reagents for medical analytical purposes; synthetic deoxyribonucleic acid and synthetic ribonucleic acid for medical use; nucleic acid amplification reagents for medical use | ACTIVE | — |
| 010 | Medical diagnostic apparatus, namely, medical diagnostic apparatus for detecting pulmonary hypertension; medical diagnostic instruments, namely, medical diagnostic apparatus for detecting pulmonary hypertension; biomedical testing apparatus, namely, apparatus for DNA and RNA testing for medical purposes; tools for medical diagnostics, namely, apparatus for DNA and RNA testing for medical purposes; medical instruments for infectious disease testing; testing apparatus for sale in kit form for medical diagnostic purposes, namely, apparatus for DNA and RNA testing for medical purposes; medical diagnostic testing apparatus, namely, apparatus for DNA and RNA testing for medical purposes; in-vitro diagnostic testing apparatus for medical use, namely, apparatus for DNA and RNA testing for medical purposes; diagnostic testing apparatus for use in molecular diagnostic procedures for medical purposes, namely, apparatus for DNA and RNA testing for medical purposes; apparatus for blood tests for medical use | ACTIVE | — |
| 044 | Medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; medical testing services relating to the diagnosis and treatment of disease; medical analysis services for the diagnosis of cancer; genetic testing for medical purposes, namely, RNA and DNA analysis for pulmonary hypertension diagnosis and prognosis; performing diagnosis of diseases; medical analysis services for the diagnosis of conditions of the human body; medical laboratory services related to the treatment of patients, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosis and treatment of persons; health assessment services by means of conducting health risk assessment surveys; health-care services; genetic testing for medical purposes; genetic testing, namely, RNA and DNA screening for medical purposes; medical analysis services for the diagnosis of pulmonary hypertension; medical screening; medical screening, namely, health screening | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MIRXES PTE. LTD.
- Other trademarks owned by MIRXES PTE. LTD.
- Other trademarks owned by MIRXES PTE. LTD.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named PHINDER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 18, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 18, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 13, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 12, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 12, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 26, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 26, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 26, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 11, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 6, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 6, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 6, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 22, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 22, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 17, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 28, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 28, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 28, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 19, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 30, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 30, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 8, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 27, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 21, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 17, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 16, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |